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Abstract
Aims Nationwide large-scale genetic and outcome studies in cohorts with hypertrophic cardiomyopathy (HCM) have not
been previously published.
Methods and results We sequenced 59 cardiomyopathy-associated genes in 382 unrelated Finnish patients with HCM and
found 24 pathogenic or likely pathogenic mutations in six genes in 38.2% of patients. Most mutations were located in sarco-
mere genes (MYBPC3, MYH7, TPM1, and MYL2). Previously reported mutations by our study group (MYBPC3-Gln1061Ter,
MYH7-Arg1053Gln, and TPM1-Asp175Asn) and a fourth major mutation MYH7-Val606Met accounted for 28.0% of cases. Mu-
tations in GLA and PRKAG2 were found in three patients. Furthermore, we found 49 variants of unknown signiﬁcance in 31
genes in 20.4% of cases. During a 6.7 ± 4.2 year follow-up, annual all-cause mortality in 482 index patients and their relatives
with HCM was higher than that in the matched Finnish population (1.70 vs. 0.87%; P < 0.001). Sudden cardiac deaths were
rare (n = 8). Systolic heart failure (hazard ratio 17.256, 95% conﬁdence interval 3.266–91.170, P = 0.001) and maximal left ven-
tricular wall thickness (hazard ratio 1.223, 95% conﬁdence interval 1.098–1.363, P < 0.001) were independent predictors of
HCM-related mortality and life-threatening cardiac events. The patients with a pathogenic or likely pathogenic mutation
underwent an implantable cardioverter deﬁbrillator implantation more often than patients without a pathogenic or likely
pathogenic mutation (12.9 vs. 3.5%, P < 0.001), but there was no difference in all-cause or HCM-related mortality between
the two groups. Mortality due to HCM during 10 year follow-up among the 5.2 million population of Finland was studied from
death certiﬁcates of the National Registry, showing 269 HCM-related deaths, of which 32% were sudden.
Conclusions We identiﬁed pathogenic and likely pathogenic mutations in 38% of Finnish patients with HCM. Four major sar-
comere mutations accounted for 28% of HCM cases, whereas HCM-related mutations in non-sarcomeric genes were rare.
Mortality in patients with HCM exceeded that of the general population. Finally, among 5.2 million Finns, there were at least
27 HCM-related deaths annually.
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Introduction
Hypertrophic cardiomyopathy (HCM), the most common
monogenic heart disease with dominant mode of inheritance,
is caused primarily by mutations in genes encoding sarco-
mere proteins. The two major genes responsible for HCM
are cardiac myosin-binding protein C (MYBPC3) and beta-
myosin heavy chain (MYH7) accounting for over a half of
the HCM cases.1 The utilization of large-scale sequencing
methods has increased the spectrum of the putative HCM-
related genes into non-sarcomeric genes, but two recent
studies have suggested that mutations in non-sarcomeric
genes are rare cause of HCM.2,3
The genetic background of HCMmay be variable across dif-
ferent populations. To our knowledge, only one study investi-
gating a large panel of cardiomyopathy-related genes in a
national HCM cohort has been published.4 The Finnish popu-
lation has unique genetic background, originated from
geographical, linguistic, and cultural isolation of the popula-
tion.5 Consequently, in Finland, the distribution of rare ge-
netic variants is different from that in other European
populations, and a founder effect is frequently observed in
the genetics of monogenic diseases.5 We have previously
identiﬁed three Finnish founder mutations in sarcomere
genes (MYBPC3-Gln1061Ter, MYH7-Arg1053Gln, and TPM1-
Asp175Asn), accounting for 24% of all cases with HCM in
Finland.6,7 However, there are no previous studies investigat-
ing large panels of cardiomyopathy-related genes using next-
generation sequencing in Finnish patients with HCM.
In early reports derived from referral centres in Europe and
the USA, HCM-related mortality was reported to be as high as
6% per year, but in a more recent report, the prognosis of
HCM has been shown to be comparable with the general
population.8 Risk stratiﬁcation and the use of implantable car-
diac deﬁbrillator (ICD) in high-risk patients has improved the
prognosis of HCM.8 In a cross-sectional setting, HCM in Finns
is characterized by a relatively benign phenotype,9 but longi-
tudinal observational studies on the natural history and the
outcome of HCM have not been previously investigated in
Finnish patients with HCM.
In Finland, forensic pathologists of the National Mortality
Registry review all deaths and the cause of death.
Autopsy is performed in a high percentage of deaths and in
all cases of sudden and unclear deaths. To our knowledge,
there are no previous studies on nationwide HCM-related
deaths.
The aim of our study was, therefore, ﬁrstly, to investigate
the genetic basis of HCM in the nationwide cohort of Finnish
patients by screening 59 cardiomyopathy-associated genes
with targeted sequencing. Secondly, we investigated HCM-
related mortality and adverse cardiovascular events in a pro-
spective outcome study including Finnish index patients and
relatives with HCM. Thirdly, the number of HCM-related
deaths among the 5.2 million population of Finland was
examined from records and death certiﬁcates of the National
Registry during the 10 year follow-up.
Patients and methods
The diagnosis of hypertrophic cardiomyopathy
The diagnosis of HCM was based on left ventricular hypertro-
phy (LVH) ≥15 mm in probands and ≥13 mm in relatives on
two-dimensional echocardiography or cardiac magnetic reso-
nance imaging in the absence of other obvious causes for
LVH.
Study cohorts and ethical approval
Our study includes three cohorts: (i) FinHCM Genetic Study
(n = 382), which includes consecutive unrelated Finnish pa-
tients with HCM, as previously described,6,10 (ii) FinHCM Out-
come Study, which consists of 482 Finnish patients with HCM
(339 probands and 143 relatives), and (iii) HCM Mortality
Study (n = 573) based on the National Mortality Registry in-
cluding all inhabitants of Finland, who deceased between
2001 and 2010, and whose cause of death was HCM.
The study protocols were in agreement with the Declara-
tion of Helsinki and were approved by the Ethics Committee
of the Kuopio University Hospital. All patients gave written in-
formed consent. The permission to use mortality data was ac-
cepted by the National Registry of Finland (Statistics Finland).
Genetic analyses of the FinHCM Genetic Study
FinHCM Genetic Study includes consecutive unrelated Finnish
patients with HCM (n = 382), recruited from 12 Finnish hospi-
tals (all ﬁve university hospitals and seven central hospitals),
as previously described.6,10 Participants of the study
underwent a screening of 59 cardiomyopathy-related genes
using the Illumina MiSeq-sequencer (Supporting Information,
Table S1). DNA was extracted from peripheral blood
leucocytes for genetic analyses. The sequencing panel was
designed to include all genes suggested to be associated with
non-syndromic cardiomyopathies at the time of the study on-
set. Sequencing methods applied in this study have been pre-
viously reported,11 and the details are presented in the
Supporting Information. All pathogenic (P)/likely pathogenic
(LP) variants were conﬁrmed by Sanger sequencing. If an
HCM-related genetic variant was found in the index patient,
it was screened in the relatives of the patients, when
possible.
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Classiﬁcation of the ﬁltered variants
Variants that underwent the ﬁltering process as described in
the Supporting Information were assigned as P, LP, variant of
uncertain signiﬁcance (VUS), likely benign, benign, or a vari-
ant with conﬂicting interpretations of pathogenicity (CON) ac-
cording to the ClinVar archive (www.ncbi.nlm.nih.gov/clinvar;
accessed 21 November 2017). For variants assigned as P, LP,
CON favouring pathogenicity (P and/or LP + VUS), or VUS, the
allele frequency in Finns and non-Finnish Europeans was ob-
tained from the Genome Aggregation Database (gnomAD
browser beta; http://gnomad.broadinstitute.org; accessed
21 November 2017).
FinHCM Outcome Study
The FinHCM Outcome Study includes 482 Finnish patients
(mean age 50.8 ± 15.0 years) with HCM (339 probands, of
whom 333 were included also in the genetic study, and 143
relatives). At baseline, the participants of the FinHCM Out-
come Study underwent a clinical and echocardiographic eval-
uation as previously described.6,10 A 24 h Holter registration
and bicycle ergometer test was performed in majority of
the patients. In many cases, cardiac magnetic resonance im-
aging was performed to verify the diagnosis of HCM.
The baseline of the Finnish Outcome Study was deﬁned by
the time of initial recruitment (between October 1994 and
April 2010). The follow-up period was until 1 January 2011 in
all patients or until the time of death if it occurred before
the end of follow-up. The mean follow-up time was
6.7 ± 4.2 years (range 0.1–16.2 years). The follow-up data were
collected from hospital medical records by the physician
recruiting the patient at baseline. Death records and certiﬁ-
cates were obtained from the National Mortality Registry (Sta-
tistics Finland) and were available in all but one patient. Causes
of death were reclassiﬁed as (i) HCM-related sudden death, (ii)
HCM-related heart failure, (iii) HCM-related atrial ﬁbrillation
and embolic stroke, and (iv) non-HCM-related death according
to data from death certiﬁcates and medical records by two ex-
perienced cardiologists (P. J. and J. K.). If the death could not
be classiﬁed as HCM-related because of another possible
cause (e.g. evidence of acute coronary syndrome related to
sudden death) or the cause of death was multifactorial, the
death was classiﬁed as HCM as a possible contributing factor.
Autopsy was performed in 26 (47%) of the deaths.
HCM Mortality Study
HCM Mortality Study (n = 573) included all inhabitants of
Finland who deceased between 2001 and 2010 and whose
principal cause of death was HCM (ICD10 Diagnosis Number
I42.1 or I42.2), or HCM was a contributing factor to death,
according to death records from the National Mortality Regis-
try. Autopsy was performed in 62% of deaths. In the present
study, two experienced cardiologists (P. J. and J. K.) reviewed
the death certiﬁcates and reclassiﬁed the cause of death as
in the FinHCM Outcome Study (see aforementioned).
Statistical analyses
Statistical analyses were performed with the IBM SPSS Statis-
tics 22.0 software (IBM, New York, NY, USA) and R statistical
software, version 3.1.1. Data are presented as mean ± stan-
dard deviation for continuous variables and n (%) for categor-
ical variables. Demographic and clinical parameters listed in
Supporting Information, Table S5 were tested with the Cox
regression analysis to investigate the factors predicting
HCM-related mortality or life-threatening cardiac events (ad-
equate ICD shock therapy, successful cardiopulmonary resus-
citation, or cardiac transplantation). The variables that were
statistically signiﬁcant (P < 0.05) in the univariate analysis
were further analyzed with a multivariate Cox proportional
hazard model. Comparisons between two groups (P/LP vs.
no P/LP mutation) were made by using the χ2 or Mann–
Whitney U test, when appropriate.
We applied Kaplan–Meier method to investigate survival.
The observed survival of the FinHCM outcome cohort was
compared with the expected survival of the Finnish general
population (n = 5.2 million) between 1995 and 2010 matched
for age and sex. Observed and expected surviving fractions
were compared by using one-sample log-rank test.
Results
FinHCM Genetic Study
Clinical characteristics
Patients included in the FinHCM Genetic Study (235 male and
147 female; mean age 53 ± 14 years) had mostly moderate
LVH with normal left ventricular (LV) dimensions and ejection
fraction (Supporting Information, Table S2). LV outﬂow tract
obstruction (pressure gradient >30 mmHg) was present in
23 patients (6%). The clinical phenotype of HCM in Finland,
particularly in those with founder mutations MYBPC3-
Gln1061Ter12–14 and TPM1-Asp175Asn,15–19 has previously
been extensively reported.6,9,20
Genetic analyses
After ﬁltering, a total of 230 different rare variants in 50
genes were found in 349 of 382 patients (Figure 1 and
Supporting Information, Tables S1 and S3). Altogether, 24
P/LP variants were found in four sarcomere (MYBPC3,
MYH7, MYL2, and TPM1) and two non-sarcomeric genes
(GLA and PRKAG2) in 146 patients (38.2%; Figure 1 and
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Table 1). A P/LP mutation was most often found in MYBPC3
(70/382, 18.3%) orMYH7 (48/382, 12.6%). The most frequent
variants were MYBPC3-Gln1061Ter (11.3%),21 MYH7-
Arg1053Gln (7.9%),22 and TPM1-Asp175Asn (6.3%),10 which
have previously been reported by our group, and MYH7-
Val606Met (2.6%). Altogether, these four sarcomere muta-
tions accounted for 28% of the HCM cases and 73% of cases
with a P/LP mutation. Mutations (P/LP) in non-sarcomeric
genes GLA and PRKAG2 were found in two and one subjects,
respectively (Table 1). In the carriers of the two GLA muta-
tions, a familial Fabry disease was found. None of the study
participants had more than one P/LP variant. The allele counts
of the P/LP mutations were zero or very low in both Finns and
non-Finnish Europeans according to the Genome Aggregation
Database. A P/LP variant was found in 119 of 143 (83.2%) of
clinically affected relatives that were included in the FinHCM
Outcome Study.
Altogether, 49 VUS or CON variants favouring pathogenic-
ity were detected in 31 different genes in 78 patients (20.4%;
Figure 1 and Supporting Information, Tables S3 and S4). Of
these patients, 58 (15.2%) did not have a P/LP mutation. Var-
iants were detected in both sarcomeric (predominantly
MYBPC3 and MYH7; 14 variants in 26 patients) and non-
sarcomeric genes (35 variants in 26 genes in 52 patients).
Most of the variants (44/49) were missense variants in single
patients. All VUS had zero to low allele counts in the Genome
Aggregation Database. For 82 rare variants, the ClinVar classi-
ﬁcation was not available.
FinHCM Outcome Study
Baseline clinical characteristics
Baseline characteristics of most of the patients of the FinHCM
Outcome Study have been reported previously.6,7,9,10,21 Base-
line clinical characteristics of all study patients are shown in
Supporting Information, Table S5. The mean maximal thick-
ness of LV on echocardiography was 20 ± 5 mm, and LV di-
mensions and ejection fraction were within the normal
limits in most patients (data not shown). Of the patients, 4
and 5% had a history of pacemaker or ICD implantation, re-
spectively. Only one patient had a cardiac resynchronization
therapy device implanted before baseline. None of the pa-
tients had undergone heart transplantation before baseline.
Deaths and cardiac events during the 6.7 year follow-up
The incidence of cardiovascular events in the FinHCM Out-
come Study are shown in Supporting Information, Table S6.
The overall survival was 89% (all-cause mortality 1.70% per
year), and 55 patients (11%) died during the follow-up
(Figures 2 and 3). All-cause mortality of the HCM outcome
cohort was higher than that of age-matched and sex-matched
general Finnish population of 5.2 million between 1995 and
2010 (Figure 3).
Of all deaths of the FinHCM Outcome Study, 38% were
HCM-related (eight sudden cardiac deaths (SCDs), nine heart
failures, and four strokes; Figure 2 and Supporting Informa-
tion, Table S7). The overall HCM-related mortality was 4.4%
(0.65% per year). Of those who suffered HCM-related death,
about half had a P/LP mutation. In 14 cases (25%), HCM was a
contributing factor to death. The cause of death was not re-
lated to HCM in 35% of the patients.
A life-threatening cardiac event occurred in nine patients
during the follow-up (an adequate ICD shock therapy in four
patients, a successful cardiopulmonary resuscitation in one
patient, and cardiac transplantation in four patients; three
of these patients died later during the follow-up). Altogether,
27 subjects suffered an HCM-related death or life-threatening
HCM event, giving the overall event rate 5.6% (0.85% per
year) (Supporting Information, Table S6). An ICD was im-
planted in 9% of study subjects. The indication for ICD was
secondary prevention in 27% and primary prevention in
63% of implantations. Bradycardia pacemaker or cardiac
resynchronization therapy was implanted in only few sub-
jects. LV outﬂow tract obstruction was treated with either
surgical myectomy or alcohol septal ablation in 4% of pa-
tients, respectively. Paroxysmal or chronic atrial ﬁbrillation
(AF) was present in 20% of patients. New-onset heart failure
Figure 1 Percentage distribution of genetic variants in 382 Finnish index
patients with hypertrophic cardiomyopathy. B, benign; CON, variant with
conﬂicting interpretations of pathogenicity; LB, likely benign; LP, likely
pathogenic; P, pathogenic; VUS, variant of uncertain signiﬁcance.
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Table 1 P/LP mutations associated with cardiomyopathy found in the FinHCM Genetic Study (n = 382)
Gene Nucleotide change Amino acid change
No. of patients
with variant,
n (%) Class (ClinVar)
Allele count
in Finns
(gnomAD)
Allele count
in European
(non-Finnish)
(gnomAD)
GLA c.658C>T p.Arg220Ter 1 P NA NA
c.1228A>G p.Thr410Ala 1 P NA NA
MYBPC3 c.655-2A>Ca 3 NAb NA NA
c.927-2A>G 1 P 0/3494 1/14 966
c.1227-13G>Aa 3 LP NA NA
c.1358dupC p.Val454fs 1 P/LP NA NA
c.1505_1509delGGTTC p.Arg502fs 3 LP NA NA
c.1575T>G p.Tyr525Ter 2 P/LP NA NA
c.2373dupG p.Trp792Valfs 4 P 0/17 280 3/67 494
c.2556_2557delCGinsTCTa,c p.Gly853Leufs 4 P NA NA
c.3181C>Ta p.Gln1061Ter 43 (11.3) P 3/16 578 0/126 472
c.3190+5G>A 5 P/LP 0/12 874 2/111 318
c.3296_3297delGG; c.3295dupG p.Gly1099fs/p.Tyr1100fs 1 P/LP 3/19 554 0/94 384
MYH7 c.1178C>T p.Ala393Val 1 LP NA NA
c.1816G>A p.Val606Met 10 (2.6) P/LP 0/3492 1/14 998
c.1987C>T p.Arg663Cys 1 P/LP NA NA
c.2155C>Ta p.Arg719Trp 1 P 0/3492 1/14 998
c.2207T>C p.Ile736Thr 1 P NA NA
c.2539_2541delAAG p.Lys847Del 2 LP NA NA
c.2770G>A p.Glu924Lys 2 P/LP NA NA
c.3158G>Aa p.Arg1053Gln 30 (7.9) LP 17/25 794 0/126 704
MYL2 c.173G>A p.Arg58Gln 1 P/LP 2/22 298 0/111 682
PRKAG2 c.905G>A p.Arg302Gln 1 P NA NA
TPM1 c.523G>Aa p.Asp175Asn 24 (6.3) P 4/25 748 1/126 700
Total 146 (38.2)
LP, likely pathogenic; NA, data not available; P, pathogenic.
aVariant has been reported in our previous studies.
bVariant was considered as a disease-causing mutation in our previous21 and present study.
cVariant was denoted A851InsT in our previous study.7
Figure 2 Distribution of the causes of death in the FinHCM Outcome Study (54 deaths) and in the HCM Mortality Study (573 deaths). HCM, hypertro-
phic cardiomyopathy.
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was diagnosed in 11% of subjects. Coronary heart disease and
cerebrovascular events were uncommon.
Predictors of hypertrophic cardiomyopathy-related death
and life-threatening hypertrophic cardiomyopathy events
In univariate Cox analysis, advanced functional class (3–4), his-
tory of AF, history of ventricular ﬁbrillation/cardiac arrest,
pacemaker implantation, diastolic or systolic heart failure at
baseline, maximal LV wall thickness, low LV ejection fraction,
and the presence of AF at Holter registration were predictors
of combined HCM-related mortality and life-threatening
HCM events (Supporting Information, Table S8). In multivari-
ate Cox proportional hazard analysis, only a history of systolic
heart failure and maximal LV wall thickness remained statisti-
cally signiﬁcant.
Differences between patients with or without a
pathogenic/likely pathogenic mutation
Of the 482 patients with HCM, 255 (136 probands and 119 rel-
atives; 52.9%) had a P/LP mutation shown in Table 1. The pa-
tients with a P/LP mutation were more often women (60.7
vs. 47.3%, P = 0.004), were younger (47.8 ± 14.6 vs.
54.1 ± 14.8 years, P < 0.001), had greater maximal LV wall
thickness (20.2 ± 5.3 vs. 18.9 ± 4.0 mm, P = 0.011), and had
smaller LV end-diastolic (44.4 ± 6.7 vs. 47.4 ± 6.9 mm,
P < 0.001) and end-systolic (27.8 ± 6.5 vs. 29.8 ± 7.6 mm,
P = 0.016) dimensions on echocardiography than those with-
out a P/LP mutation.
During the follow-up, the patients with a P/LP mutation
underwent an ICD implantation more often than patients
without a P/LP mutation (12.9 vs. 3.5%, P < 0.001). All-
cause/HCM-related mortality or combined HCM mortality
and life-threatening events did not differ between the two
groups (data not shown).
HCM Mortality Study
Between 2001 and 2010, 573 individuals (56% male, age at
death 68.1 ± 16.6 years; 6% <40 years of age) in Finland suf-
fered HCM-related death. HCM was assigned as the principal
cause of death by the National Mortality Registry in 393 of
these patients (69%). Two cardiologists of the present study
reclassiﬁed HCM as the principal cause of death in 269 of
573 cases (47% of all deaths, age at death 63.3 ± 16.5 years;
Figure 2), including 186 sudden cardiac (32%), 71 heart failure
(12%), and 12 stroke deaths (2%), respectively. In 266 subjects,
HCM (46%) was reclassiﬁed as a contributing factor to death.
Discussion
Principal ﬁndings
Targeted sequencing of 59 genes associated with cardiomyop-
athies revealed P/LP mutations in 38% of HCM cases in the na-
tionwide FinHCM Genetic Study and VUS or CON variants
favouring pathogenicity in 20%. The four most frequent sarco-
meric mutations accounted for 28% of the HCM cases, indicat-
ing that these few major mutations explain a substantial
number of HCM cases in Finland. In contrast, P/LP variants in
non-sarcomeric genes were rare and found only in GLA and
PRKAG2 genes in three patients. In the FinHCM Outcome
Study, annual all-cause mortality exceeded that of the age-
matched and gender-matched general Finnish population. His-
tory of systolic heart failure and maximal LV wall thickness
were independent predictors of HCM-related mortality and
life-threatening cardiac events. The patients with a P/LP muta-
tion underwent an ICD implantation more often than patients
without a P/LP mutation, but all-cause/HCM-related mortality
or combined HCM mortality and life-threatening events did
not differ between the two groups. Finally, among 5.2 million
Finns, there were at least 27 HCM-related deaths annually.
FinHCM Genetic Study
A P/LP mutation was identiﬁed in 38% of the cases, mainly in
sarcomere genes. P/LP variants in non-sarcomeric genes were
rare. There are only few studies on targeted sequencing of
comprehensive cardiomyopathy gene panels in large patient
populations with HCM2,4,23–25 and only one in a national
HCM cohort.4 Back in 2003, a French group reported a
disease-causing mutation in 63% (124/197) of unrelated
HCM patients who underwent a screening of only nine core
sarcomeric protein genes.26 In their study, the pathogenicity
of variants was determined by traditional methods (e.g. co-
segregation with HCM and absence in controls). In a more
recent report, in the screening of 41 genes, a potential
HCM- related variant was found in 64% of 223 patients, but
pathogenicity of variants was not validated against any cur-
rently available genetic databases.4 In another recent study,
in 31 genes tested, P/LP variants were found in 39.9% of
Figure 3 Kaplan–Meier survival in the FinHCM Outcome Study (n = 482)
compared with expected all-cause mortality in the general Finnish popu-
lation matched for age and sex. CI, conﬁdence interval; SMR, standard-
ized mortality ratio.
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cases almost exclusively in sarcomeric genes.2 Expanded gene
panels do not appear to substantially increase sensitivity of
HCM testing beyond gene panels including eight core sarco-
mere genes, GLA, PRKAG2, and LAMP2.23 Generally, because
of the variability in patient cohorts, genetic methodology, and
interpretation of results, the comparison of the results of
published studies with targeted sequencing is challenging.
The present study highlights the fundamental role of four
sarcomeric mutations in the pathogenesis of HCM in the Finn-
ish population. We have previously reported three major
Finnish HCM-causing mutations, MYBPC3-Gln1061Ter,
MYH7-Arg1053Gln, and TPM1-Asp175Asn, which are rare in
other populations.6,7 Now, we report another major muta-
tion, MYH7-Val606Met, in 2.6% of patients. These four muta-
tions explained almost one-third of the HCM cases and more
than two-thirds of the cases with a P or LP mutation. Like-
wise, in a nationwide HCM study in Iceland, a single MYBPC3
mutation c.927-2A>G accounted for 58% of all HCM cases.27
The occurrence of distinct major mutations for HCM in genet-
ically isolated populations emphasizes the need for national
genetic studies in HCM.27,28
In our study, 15% of the patients had a VUS or CON variant
favouring pathogenicity without another likely causal variant
for HCM. Moreover, for a considerable number of rare vari-
ants, ClinVar classiﬁcation was not available. Some of these
variants might be actual disease-causing mutations, and fur-
ther studies are needed to determine their causality. Finally,
a considerable number of patients did not have a P/LP,
VUS, or CON variant in any of the genes tested. Further stud-
ies are needed to investigate if these patients have mutations
in unknown genes for HCM, in regulatory non-coding regions
of already identiﬁed causal genes, or LVH-inducing variants in
multiple genes.
FinHCM Outcome Study
In the FinHCM Outcome Study, the annual all-cause mortality
(1.70%) was higher than that expected (0.87%) in the matched
general Finnish population, and annual HCM-related mortality
was 0.65%. There are only a few previous mortality studies in-
cludingmainly US patient populations with HCM.29,30 All-cause
mortality in the present study is in agreement with a study of
US HCM patients29 but contrasts a retrospective study of 706
HCM patients, where the overall survival was not different
from that of matched White US population.30 The annual
HCM-related mortality in the present study is comparable with
HCM-related mortality reported in other adult HCM co-
horts.29,30 A rather favourable outcome in our study is likely
to be explained by the inclusion of relatives, who usually have
milder disease than probands. Furthermore, if the 14 deaths
classiﬁed as contributors to death were classiﬁed as HCM
deaths, HCM-related mortality would have been higher.
Sudden cardiac death and heart failure were the major
mechanisms of HCM-related death in the present study,
followed by embolic stroke. In a previous study, the mecha-
nisms of HCM deaths were most often SCD and heart failure.29
A history of systolic heart failure and maximal LV wall thick-
ness, both well-known risk factors for HCM-related death,8
were independent predictors of combined HCM-related
death and life-threatening events. Many of the other risk
factors for SCD did not predict HCM-related mortality and
life-threatening HCM events in the present study, possibly
because of small number of deaths.
The presence of a P/LP mutation was associated with fe-
male gender, younger age, thicker LV wall, and smaller LV di-
mensions. The phenotypic expression of the two major
mutations MYBPC3-Gln1061Ter and TPM1-D175N has been
investigated in detail in our previous study.6 Although there
was no difference in HCM-related mortality or combined
HCM-related mortality and life-threatening events, patients
with a P/LP mutation were more likely to undergo an ICD im-
plantation. In a recent study, it was reported that young age
at diagnosis and the presence of a sarcomere mutation are
associated with an adverse clinical outcome.31
HCM Mortality Study
The HCM Mortality Study shows that in Finland, with a popu-
lation of 5.2million, at least 27 deaths annually are attributed
to HCM. To our knowledge, there are no previous nationwide
studies on HCM-related deaths. About 70% of the reclassiﬁed
HCM-related deaths in Finland were sudden. Undoubtedly,
post-mortem diagnosis of HCM at autopsy may be challeng-
ing. However, our ﬁndings suggest that a considerable num-
ber of subjects suffer an HCM-related death in Finland and
that the proportion of SCDs compared with other causes of
death is higher at the population level than that in patient
populations participating in clinical studies. As the HCM Mor-
tality Study cohort was based on patients with an HCM-
related death according to death certiﬁcates, the actual
HCM-related mortality at the population level might be even
higher. For example, the low frequency of embolic stroke in
the HCM Mortality Study cohort might be explained by that
not all fatal embolic strokes suffered by HCM patients were
classiﬁed as HCM-related in death certiﬁcates.
Clinical implications
Screening of a panel of 59 cardiomyopathy genes identiﬁes a
causative mutation in about 40% of Finnish patients with
HCM. Screening of the four major mutations identiﬁes genetic
cause for HCM in about 30% and should be a primary genetic
testing in Finland, even if large-scale genetic panels are used.
All-cause mortality exceeded the expected all-cause mor-
tality in the general Finnish population, but the rate of
HCM-related deaths and life-threatening HCM events was rel-
atively low. However, patients with marked cardiac hypertro-
phy or heart failure should be monitored carefully to reduce
HCM-related mortality. Finally, a considerable number of
HCM-related deaths, particularly SCDs, in the Finnish
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population suggest that there are undiagnosed and untreated
patients with HCM who would beneﬁt of more effective diag-
nostic and treatment options.
Strengths and limitations of the study
First, a comprehensive panel of 59 genes associated with car-
diomyopathy was used in the screening of the large nation-
wide FinHCM genetic cohort, but not all putative genes
associated with HCM were investigated. Thus, some dis-
ease-causing mutations may have been missed. However, as
the frequency of P/LP mutations in other than the eight core
sarcomeric genes is very low in the present study and few re-
cently published reports,2,3 major mutations were probably
not missed.
Second, pathogenicity of the genetic variants was deter-
mined according to the present ClinVar archive classiﬁcation.
The ClinVar classiﬁcation, however, was not available for all
rare variants, and some of the variants classiﬁed as variants
with unknown signiﬁcance may be disease causing.
Third, for variants assigned as P, LP, or VUS, the allele fre-
quencies in Finns and non-Finnish Europeans were obtained
from the Genome Aggregation Database. Only few previous
studies have included population-based allele frequencies to
investigate rare protein-altering variants for HCM.2,4
Fourth, for the present study, medical records and mortal-
ity data from the National Mortality Registry were available
for almost all subjects and deaths, and autopsy was per-
formed in a considerable number of deaths, increasing reli-
ability of our ﬁndings.
Conclusions
By using targeted genetic testing of a large cardiomyopathy
panel, a causative mutation was found in approximately
40% of Finnish patients with HCM. In Finnish patients, the ge-
netic proﬁle of HCM is unique, as four major mutations in the
sarcomeric genes account for one-third of all cases and three-
quarters of cases with P or LP mutation. HCM-related mortal-
ity in patients with diagnosed HCM was low, but all-cause
mortality was higher than that expected in the general popu-
lation. Finally, according to the National Registry, at least ﬁve
HCM-related deaths per million inhabitants occur annually in
Finland.
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